Cost-Effectiveness of HIV Rescreening During Late Pregnancy to Prevent Mother-to-Child HIV Transmission in South Africa and Other Resource-Limited Settings
Authors:
- 1 June 2006
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 42 (2) , 213-221
Abstract
Summary: A decision analysis model, from a health care system perspective, was used to assess the cost-effectiveness of HIV rescreening during late pregnancy to prevent perinatal HIV transmission in South Africa, a country with high HIV prevalence and incidence among pregnant women. Because new HIV prenatal prophylactic and pediatric antiretroviral therapy (ART) regimens are becoming more widely available, the study was carried out with different combinations of the two. With an estimated HIV incidence during pregnancy of 2.3 per 100 person-years, HIV rescreening would prevent additional infant infections and result in net savings when zidovudine plus single-dose nevirapine or single-dose nevirapine is used for perinatal HIV prevention, and ART was available to treat perinatally HIV-infected children. The cost savings were robust over a wide range of parameter values when ART was available to treat perinatally HIV-infected children but were more sensitive to variations around the baseline when ART was not available. The minimum time interval between the initial and repeat screens would be from 3 to 18 weeks, depending on prophylactic and treatment regimens, for HIV rescreening to be cost saving. Overall, HIV rescreening late in pregnancy in high-prevalence, resource-limited settings such as South Africa would be a cost-effective strategy for reducing mother-to-child transmission.Keywords
This publication has 24 references indexed in Scilit:
- Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective studyThe Lancet, 2005
- Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral TherapyNew England Journal of Medicine, 2005
- Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in ThailandNew England Journal of Medicine, 2004
- Prevention of Mother‐to‐Child Transmission of HIV‐1 through Breast‐Feeding: Past, Present, and FutureThe Journal of Infectious Diseases, 2004
- Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: Recommendations of the UNAIDS Reference Group on Estimates, Modelling and ProjectionsAIDS, 2002
- The Cost Effectiveness of Combination Antiretroviral Therapy for HIV DiseaseNew England Journal of Medicine, 2001
- Cost-Effective Use of Nevirapine to Prevent Vertical HIV Transmission in Sub-Saharan AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Natural History of Human Immunodefiency Virus Type 1 Infection in Children: A Five-Year Prospective Study in RwandaPediatrics, 1999
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999
- Acceptability of voluntary HIV testing by pregnant women in developing countriesAIDS, 1998